Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec:108:102673.
doi: 10.1016/j.ceca.2022.102673. Epub 2022 Nov 12.

Calcium signaling: A therapeutic target to overcome resistance to therapies in cancer

Affiliations
Free article
Review

Calcium signaling: A therapeutic target to overcome resistance to therapies in cancer

Olivier Romito et al. Cell Calcium. 2022 Dec.
Free article

Abstract

Innate and acquired resistances to therapeutic agents are responsible for the failure of cancer treatments. Due to the multifactorial nature of resistance, the identification of new therapeutic targets is required to improve cancer treatment. Calcium is a universal second messenger that regulates many cellular functions such as proliferation, migration, and survival. Calcium channels, pumps and exchangers tightly regulate the duration, location and magnitude of calcium signals. Many studies have implicated dysregulation of calcium signaling in several pathologies, including cancer. Abnormal calcium fluxes due to altered channel expression or activation contribute to carcinogenesis and promote tumor development. However, there is limited information on the role of calcium signaling in cancer resistance to therapeutic drugs. This review discusses the role of calcium signaling as a mediator of cancer resistance, and assesses the potential value of combining anticancer therapy with calcium signaling modulators to improve the effectiveness of current treatments.

Keywords: Calcium channels; Calcium signaling; Cancer; Chemoresistance; Potassium channels.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest Mohamed Trebak is a paid consultant of Seeker Biologics Inc. The other authors declare that they have no conflict of interest.

Publication types